Cite
Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial
MLA
Carlo Gambacorti-Passerini, et al. “Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial.” Blood, vol. 136, Nov. 2020, pp. 34–35. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........17447b8b0d46b784726fa0a92b0ef72a&authtype=sso&custid=ns315887.
APA
Carlo Gambacorti-Passerini, Simon Purcell, Vamsi Kota, Tim H. Brümmendorf, Jorge E. Cortes, Philipp le Coutre, Pia Raanani, Eric Leip, Valentín García-Gutiérrez, Andrea Viqueira, & Henrik Hjorth-Hansen. (2020). Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial. Blood, 136, 34–35.
Chicago
Carlo Gambacorti-Passerini, Simon Purcell, Vamsi Kota, Tim H. Brümmendorf, Jorge E. Cortes, Philipp le Coutre, Pia Raanani, et al. 2020. “Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial.” Blood 136 (November): 34–35. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........17447b8b0d46b784726fa0a92b0ef72a&authtype=sso&custid=ns315887.